Led · Seed · Dec 2025

Founded in 2023 in Basel, Switzerland, Allegria Therapeutics is building a differentiated portfolio of proprietary molecules that target the pathways driving uncontrolled mast-cell activation. The company’s lead program is advancing toward pre-clinical candidate nomination, while several discovery-stage programs are also progressing. Allegria leverages collaborations with experts such as Prof. Dr. Martin Metz at Berlin’s Charité and Ap. Prof. Dr. Philipp Starkl at the Medical University of Vienna to accelerate its research. Its small but highly experienced core team and advisory board are focused on delivering first-in-class and best-in-disease therapies for allergic and inflammatory conditions. The firm’s recent USD 5.1 million seed extension brings additional capital to support lead-program advancement and discovery efforts, positioning the company for future clinical development milestones.

Participated · Series C · Jan 2011

DBV Technologies develops an epicutaneous patch technology to deliver allergens to the skin for Epicutaneous Immunotherapy (EPIT), targeting food allergies such as peanut and milk. Its proprietary patch maintains an allergen on the skin for repeated and prolonged periods to obtain clinical desensitization. The company secured €19.4M ($25.5M) in a Series C financing to advance that patch technology and its clinical program. The financing was co-led by InnoBio Fund and Lundbeckfond Ventures and included strategic and financial investors. DBV is based in Paris, France. Aelios Finance advised the company on the transaction.